Skip to main content
Publication date
2017 Jul 01
Authors
Long, GV Flaherty, KT Stroyakovskiy, D Gogas, H Levchenko, E de Braud, F Larkin, J Garbe, C Jouary, T Hauschild, A Chiarion-Sileni, V Lebbe, C Mandala, M Millward, M Arance, A Bondarenko, I Haanen, JBAG Hansson, J Utikal, J Ferraresi, V Mohr, P Probachai, V Schadendorf, D Nathan, P Robert, C Ribas, A Davies, MA Lane, SR Legos, JJ Mookerjee, B Grob, JJ
Author KI Usernames
Hansson, J|johhan
Pubmed ID
28475671
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Doctype
Article
KI Connection
Låg
Mesh SV
Behandlingsresultat Dubbelblindmetod Hudtumörer Imidazoler Kaplan-Meiers skattning Kombinationsterapi med cellgifter Läkemedelstillförselschema Melanom Mutation Människa Oximer Proteinkinashämmare Proto-onkogenproteiner B-raf Pyridoner Pyrimidinoner Riskfaktorer Sjukdomsfri överlevnad Sjukdomsförlopp Tidsfaktorer Tumörmarkörer
Mesh EN
Antineoplastic Combined Chemotherapy Protocols Biomarkers, Tumor Disease-Free Survival Disease Progression Double-Blind Method Drug Administration Schedule Imidazoles Kaplan-Meier Estimate Melanoma Mutation Oximes Protein Kinase Inhibitors Proto-Oncogene Proteins B-raf Pyridones Pyrimidinones Risk Factors Skin Neoplasms Time Factors Treatment Outcome
First date
2018-12-04T22:17:26.032Z